| [January 30, 2014] |
 |
Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing
NEW BRIGHTON, Minn. --(Business Wire)--
Regulatory News:
Cellectis plant sciences, the plant genome engineering company and
subsidiary of Cellectis SA (Paris:ALCLS), has signed two new agreements
with Bayer CropScience, a subsidiary of Bayer AG and a leader in the
areas of seeds, crop protection and non-agricultural pest control, on
gene editing in plants. The agreements extend the companies' existing
partnership to introduce targeted modifications to selected plant genes
and genomes. The financial terms of these agreements are not disclosed.
The first aim of this extended partnership is to collaboratively create
commercial traits for the canola seed market using new technologies
developed by Cellectis plant sciences. The second aim is to provide
Bayer with access to technologies that enable the directed engineering
of plant genomes, such as gene stacking and targeted mutagenesis, for
the development of improved crops.
"These novel technologies work efficiently in plant cells and will be
an important tool to improve crops," said Catherine Feuillet, Head
of Trait Research at Bayer CropScience. "They facilitate the creation
of specific modifications in the plant genome or genes and thus minimize
the genetic footprint left behind."
"These new agreements position Cellectis plant sciences as a key
partner for Bayer CropScience," commented Luc Mathis, CEO of
Cellectis plant sciences. "Following the technical success we have
achieved with all our programs in potatoes and oil crops, such as
soybean and canola, the development of new commercial products relevant
for the food industry has become the focus of our company."
About Cellectis plant sciences
Established in March 2010,
Cellectis plant sciences is a subsidiary of Cellectis (Alternext: ALCLS)
dedicated to the applications of nucleases in plants. Its main mission
is to increase and accelerate usage of Cellectis's proprietary
technology in agricultural biology, broaden the compny's platform to
attract new and expanded licensing opportunities and explore the
development of proprietary traits for selected applications. Cellectis
plant sciences is located in New Brighton, Minnesota, USA. Professor
Daniel Voytas, Chief Scientific Officer of Cellectis plant sciences, is
also Director of the University of Minnesota Center for Genome
Engineering. For further information, please visit our website: www.cellectis.com
About Cellectis
Cellectis is a biopharmaceutical company
focused on oncology. The company's mission is to develop a novel
generation of therapy based on allogeneic T-cell to treat cancer.
Cellectis capitalizes on its 14 years of expertise in genome engineering
-based on TALEN™, meganuclease, and, the state-of-the-art
electroporation technology Pulsagile- to create the 4th
generation of cancer immunotherapy to treat leukemia and solid tumors.
Cellectis adoptive cancer immunotherapy to cure chronic and acute
leukemias is based on the first allogeneic T-cell Chimeric Antigen
Receptor (CAR) technology. CAR technologies are designed to target cell
surface antigens expressed on cells. These treatments reduce toxicities
associated with current chemotherapeutics and have the potential for
curative therapy. The Cellectis Group is focused on life sciences and
use leading genome engineering technologies to build innovative products
in various fields and markets. Cellectis is listed on the NYSE Alternext
market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.
About Bayer CropScience
Bayer is a global enterprise with
core competencies in the fields of health care, agriculture and
high-tech materials. Bayer CropScience, the subgroup of Bayer AG
responsible for the agricultural business, has annual sales of EUR 8,383
million (2012) and is one of the world's leading innovative crop science
companies in the areas of seeds, crop protection and non-agricultural
pest control. The company offers an outstanding range of products
including high value seeds, innovative crop protection solutions based
on chemical and biological modes of action as well as an extensive
service backup for modern, sustainable agriculture. In the area of
non-agricultural applications, Bayer CropScience has a broad portfolio
of products and services to control pests from home and garden to
forestry applications. The company has a global workforce of 20,800 and
is represented in more than 120 countries.
This and further news is
available at: www.press.bayercropscience.com
Disclaimer
This press release and the information contained
herein do not constitute an offer to sell or subscribe, or a
solicitation of an offer to buy or subscribe for shares in Cellectis in
any country. This press release contains forward-looking statements that
relate to the Company's objectives based on the current expectations and
assumptions of the Company's management only and involve unforeseeable
risk and uncertainties that could cause the Company to fail to achieve
the objectives expressed by the forward-looking statements.
[ Back To TMCnet.com's Homepage ]
|
